ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

May 1, 2020

On April 30, the Centers for Medicare & Medicaid Services (CMS) released a second Interim Final Rule establishing new regulatory waivers and rule changes to increase flexibility for health care providers during the COVID-19 public health emergency (PHE). These waivers and rule changes further aim to expand telehealth, make it easier for Medicare and Medicaid beneficiaries to get tested for COVID-19, increase hospital capacity, augment the health care workforce, and decrease administrative burden.

April 29, 2020

On April 28, 2020, the Food and Drug Administration granted accelerated approval to a new dosing regimen of 400 mg every six weeks for pembrolizumab (KEYTRUDA®, Merck) across all currently approved adult indications, in addition to the current 200 mg every three weeks dosing regimen.

April 29, 2020

On April 29, 2020, the Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

April 28, 2020

The Association for Clinical Oncology (ASCO) joined hundreds of other health organizations in signing onto four separate letters to Congress regarding future COVID-19 legislation as part of an effort to ensure patient access to high-quality, high-value cancer care during the pandemic. The four comment letters address different areas of cancer care delivery system, such as the American Medical Association letter, the Cancer Care Community letter, the Step Therapy letter, and the Coalition to Improve Access to Cancer Care letter.

April 28, 2020

On April 26, 2020, the Centers for Medicare & Medicaid Services (CMS) announced that it is reevaluating the amounts that will be paid under its Accelerated Payment Program and suspending its Advance.

April 28, 2020

The latest legislative package aimed at stabilizing the United States (U.S.) economy and bolstering the health care system during the COVID-19 crisis was recently signed into law. The ‘‘Paycheck Protection Program and Health Care Enhancement Act,’’ provides about $475 billion to key programs under the CARES Act, including the Paycheck Protection Program (PPP), and provides additional funds for COVID-19 testing and to aid hospitals and small businesses.

April 27, 2020

MedWatch Safety Alert was added to the FDA MedWatch webpage titled Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication.

April 24, 2020

On April 22, HHS announced the allocation of an additional $40.4 billion from the Public Health and Social Services Emergency Fund.

April 23, 2020

The American Society of Clinical Oncology (the Society) and its affiliate organization the Association for Clinical Oncology (the Association) announced the results of a survey that tracked the initial impact of the COVID-19 pandemic on cancer clinical trials, highlighted a new research initiative to address the data gap on the coronavirus’ effect on individuals with cancer, and set forth a road to recovery as the cancer care delivery system prepares for life after COVID-19.

April 22, 2020

On April 22, 2020, the Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy (TRODELVYTM, Immunomedics, Inc.) for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease. 

April 22, 2020

The American Society of Clinical Oncology (ASCO) and the Association for Clinical Oncology (ASCO) released a news release announcing the COVID-19 and Cancer: Addressing a Healthcare System in Crisis presscast. 

April 20, 2020

The American Society of Clinical Oncology (ASCO) and the Association for Clinical Oncology (ASCO) released a news release announcing the COVID-19 and Cancer: Addressing a Healthcare System in Crisis presscast. 

April 20, 2020

On April 17, 2020, the Food and Drug Administration granted accelerated approval to pemigatinib (PEMAZYRE™, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

April 20, 2020

JCO Oncology Practice published an article and accompanying infographic  that examine the impact pharmacy benefit managers (PBMs) have on cancer care delivery. The article is part of the American Society of Clinical Oncology’s (ASCO) State of Cancer Care in America series, which explores challenges and opportunities in today’s oncology delivery system.

April 17, 2020

On April 17, 2020, the Food and Drug Administration approved tucatinib (TUKYSA, Seattle Genetics, Inc.) in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Pages